Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HUCS001
- Development stage
- Preclinical
- Lead developer
- Rainbow
- Modality
- Stem Cell Therapies → Cell Therapies
01
Overview
HUCS001 is an autologous bone marrow-derived stem cell therapy being developed by Rainbow for chronic-phase spinal cord injury. It is a regenerative cell therapy product that uses a patient's own bone marrow-derived cells with the intent to promote tissue repair, neural regeneration, engraftment, and functional recovery after established spinal cord damage. Based on Rainbow's pipeline information, HUCS001 is in preclinical development, and published papers have been referenced by the company for this program.
- Other names
- HUCS001 Rainbow cell therapyHUCS-001 Rainbow cell therapyHUCS 001 Rainbow cell therapyautologous bone marrow-derived stem cells
Beyond the preview
Go deeper on HUCS001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HUCS001.